These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 12894896)
1. Phase-1 studies of malariotherapy for HIV infecton. Chen X; Heimlich HJ; Xiao B; Liu S; Lu Y; Rao J; Spletzer EG Chin Med Sci J; 1999 Dec; 14(4):224-8. PubMed ID: 12894896 [TBL] [Abstract][Full Text] [Related]
2. Impact of acute vivax malaria on the immune system and viral load of HIV-positive subjects. Chen X; Xiao B; Shi W; Xu H; Gao K; Rao J; Zhang Z Chin Med J (Engl); 2003 Dec; 116(12):1810-20. PubMed ID: 14687465 [TBL] [Abstract][Full Text] [Related]
3. Malariotherapy for HIV patients. Heimlich HJ; Chen XP; Xiao BQ; Liu SG; Lu YH; Spletzer EG; Yao JL Mech Ageing Dev; 1997 Feb; 93(1-3):79-85. PubMed ID: 9089572 [TBL] [Abstract][Full Text] [Related]
4. Procedure and clinical assessments of malariotherapy: recent experience in 20 HIV patients. Chen X; Xiao B; Xu H; Shi W; Gao K; Rao J Chin Med J (Engl); 2003 Jul; 116(7):1016-21. PubMed ID: 12890375 [TBL] [Abstract][Full Text] [Related]
5. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS]. Halota W; Jaruga B; Pawłowska M Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343 [TBL] [Abstract][Full Text] [Related]
6. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191 [TBL] [Abstract][Full Text] [Related]
7. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine. Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798 [TBL] [Abstract][Full Text] [Related]
8. HLA class I soluble antigen serum levels in HIV-positive subjects--correlation with cellular and serological parameters. Puppo F; Orlandini A; Ruzzenenti R; Comuzio S; Salamito A; Farinelli A; Stagnaro R; Indiveri F Cancer Detect Prev; 1990; 14(3):321-3. PubMed ID: 2117484 [TBL] [Abstract][Full Text] [Related]
9. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment. Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742 [TBL] [Abstract][Full Text] [Related]
10. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018 [TBL] [Abstract][Full Text] [Related]
11. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332 [TBL] [Abstract][Full Text] [Related]
12. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. Stein DS; Lyles RH; Graham NM; Tassoni CJ; Margolick JB; Phair JP; Rinaldo C; Detels R; Saah A; Bilello J J Infect Dis; 1997 Nov; 176(5):1161-7. PubMed ID: 9359714 [TBL] [Abstract][Full Text] [Related]
13. Evidence of active cytomegalovirus infection in clinically stable HIV-infected individuals with CD4+ lymphocyte counts below 100/microliters of blood: features and relation to risk of subsequent CMV retinitis. MacGregor RR; Pakola SJ; Graziani AL; Montzka DP; Hodinka RL; Nichols CW; Friedman HM J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):324-30. PubMed ID: 7552494 [TBL] [Abstract][Full Text] [Related]
14. Managing HIV. Part 4: Primary therapy. 4.3 The laboratory in managing HIV infection. Dwyer DE; Adelstein S; Cunningham AL; Merigan TC Med J Aust; 1996 Mar; 164(5):301-3. PubMed ID: 8628167 [TBL] [Abstract][Full Text] [Related]
15. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. Aziz N; Nishanian P; Taylor JM; Mitsuyasu RT; Jacobson JM; Dezube BJ; Lederman MM; Detels R; Fahey JL J Infect Dis; 1999 Apr; 179(4):843-8. PubMed ID: 10068579 [TBL] [Abstract][Full Text] [Related]
16. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults. Erikstrup C; Kallestrup P; Zinyama-Gutsire RB; Gomo E; Butterworth AE; Pedersen BK; Ostrowski SR; Gerstoft J; Ullum H AIDS; 2007 Nov; 21(17):2283-91. PubMed ID: 18090276 [TBL] [Abstract][Full Text] [Related]
17. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy. Chitra P; Bakthavatsalam B; Palvannan T Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045 [TBL] [Abstract][Full Text] [Related]
18. Decline in beta-2 microglobulin levels after antitubercular therapy in tubercular patients with HIV infection. Wanchu A; Arora S; Bhatnagar A; Sud A; Bambery P; Singh S Indian J Chest Dis Allied Sci; 2001; 43(4):211-5. PubMed ID: 18610664 [TBL] [Abstract][Full Text] [Related]